CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Loteprednol etabonate ophthalmic suspension 0.5% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00834171
NCT00834171N/ACompleted
CompareCT.gov

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Allergan·observational·Posted Feb 3, 2009·Updated Sep 26, 2011

In Brief

An observational study evaluating Loteprednol etabonate ophthalmic suspension 0.5% and Loteprednol etabonate (0.5%) and tobramycin (0.3%). for Ocular Hypertension. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2009
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.4 years ago

Interventions

Loteprednol etabonate ophthalmic suspension 0.5%drug

Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician

Loteprednol etabonate (0.5%) and tobramycin (0.3%).drug

Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.